XML 18 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2014
Income Statement [Abstract]      
Molecular diagnostic testing $ 705.7 $ 695.5 $ 748.2
Pharmaceutical and clinical services 48.1 27.6 30.0
Total revenue 753.8 723.1 778.2
Costs and expenses:      
Cost of molecular diagnostic testing 132.8 132.8 96.1
Cost of pharmaceutical and clinical services 24.5 14.6 13.1
Research and development expense 70.6 75.5 67.5
Selling, general, and administrative expense 359.1 366.0 327.1
Total costs and expenses 587.0 588.9 503.8
Operating income 166.8 134.2 274.4
Other income (expense):      
Interest income 0.9 0.4 5.4
Other 1.2 0.3 (2.0)
Total other income: 2.1 0.7 3.4
Income before income tax 168.9 134.9 277.8
Income tax provision 43.6 54.7 101.6
Net income $ 125.3 $ 80.2 $ 176.2
Earnings per share:      
Basic $ 1.79 $ 1.12 $ 2.33
Diluted $ 1.71 $ 1.08 $ 2.25
Weighted average shares outstanding:      
Basic 70.0 71.3 75.7
Diluted 73.4 74.5 78.2